American Society of Hirudotherapy

Outcomes of flap salvage with medicinal leech therapy

Retrospective cohort published in Microsurgery (2012)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyClinical TrialsSafety & Infection ControlNguyen MQ et al. · Microsurgery, 2012

Abstract

Medicinal leech therapy (MLT) to salvage venous congestion in native skin and local flaps is commonly practiced. However, the role of MLT in compromised regional and free flaps remains unclear. Leeches were used in 39 patients to treat venous congestion in native skin (n = 5), local flaps (n = 6), regional flaps (n = 14), and free flaps (n = 14). There were no total losses in patients with compromised native skin or local flaps. One patient who had received a radial forearm free flap expired before flap outcome could be assessed, and was excluded from analysis. Of the remaining 27 regional and free flaps, 33.3% were salvaged, 33.3% were partially salvaged, and 33.3% were lost. Means of 38.3 ± 34.0, 101.0 ± 11.2, and 157.9 ± 224.4 leeches and 1.7 ± 3.6, 3.2 ± 4.4, and 5.6 ± 5.2 units of blood were required for the salvaged, partially salvaged, and lost groups, respectively. Twenty-two patients required blood transfusion (57.9%). No patients developed wound infection with Aeromonas hydrophilia. Two patients developed donor site hematomas, and four patients developed recipient site hematomas. MLT is efficacious in congested native skin and local flaps. Some regional and free flaps can be totally or partially salvaged. However, the morbidity of MLT must be weighed against the risks of flap loss.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyEvaluation StudyJournal Article
Indexed MeSH termsAdultAgedAged, 80 and overFemaleGraft SurvivalHumansHyperemiaLeechingMaleMiddle AgedPostoperative ComplicationsPlastic Surgery Procedures

Summary

Of 39 patients receiving medicinal leech therapy for venous congestion, 33.3% of regional and free flaps were fully salvaged and 33.3% partially salvaged. 57.9% required blood transfusion; no Aeromonas wound infections were observed.

Why This Matters for Hirudotherapy

This study reported outcomes of medicinal leech therapy (MLT) for venous congestion in 39 patients with native skin (n=5), local flaps (n=6), regional flaps (n=14), and free flaps (n=14), finding no losses in native skin or local flaps, while among the 27 assessable regional and free flaps one-third each were salvaged, partially salvaged, or lost. For ASH and hirudotherapy, this is directly relevant clinical evidence: it quantifies MLT effectiveness across flap types and reports practical morbidity metrics including a 57.9% transfusion rate, mean leech usage by outcome group, and no Aeromonas hydrophila wound infections. A key caveat is that without a comparison group, the study cannot establish efficacy relative to alternative salvage methods, and reported outcomes may reflect patient selection or practice expertise.

Citation

Outcomes of flap salvage with medicinal leech therapy.

Nguyen MQ et al. · Microsurgery, 2012

Added to ASH library: May 26, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.